Keyphrases
Obstructive Sleep Apnea
100%
Pulmonary Capillary Wedge Pressure
55%
Pressure Formula
55%
Detection Method
55%
Pulmonary Tuberculosis
50%
Diabetes Mellitus Type 2
38%
Jakarta
36%
Tuberculosis Patients
33%
Chronic Obstructive Pulmonary Disease
33%
CHAID
32%
Tuberculosis
31%
Prediction Model
30%
COVID-19
30%
Risk Factors
30%
Risk Prediction Model
27%
Obstructive Sleep Apnea Risk
27%
Circulatory Disease
27%
Chronic Obstructive Pulmonary Disease Patient
27%
Type 2 Diabetes Mellitus (T2DM)
27%
Colloids
27%
Decision Tree Method
27%
Pre-diabetes (pre-DM)
27%
Albumin
27%
Echocardiography
27%
Evidence-based Case Report
27%
Partial Least Squares Structural Equation Modeling (PLS-SEM)
27%
Large-volume Paracentesis
27%
Atrial Fibrillation
27%
DOTS Strategy
27%
Predictive Success
27%
Tuberculosis Treatment
27%
D-dimer
27%
Image Features
27%
Feature-based
27%
Fibrin Monomer
27%
Computed Tomography
27%
Lung Field
27%
Viral Pneumonia
27%
COVID-19 Severity
27%
Diastolic Dysfunction
27%
Scanned Image
27%
Body Mass Index
21%
Confidence Level
20%
Paracentesis-induced Circulatory Dysfunction
18%
Multidrug-resistant Tuberculosis (MDR-TB)
16%
DM Type 2
13%
Obesity
13%
Severity Level
13%
Ground-glass Opacity
13%
Waist Circumference
12%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
55%
Obstructive Sleep Apnea
55%
Pulmonary Artery
55%
Medicine
32%
Partial Least Squares Regression
27%
Tuberculosis Treatment
27%
Echocardiography
27%
Impaired Glucose Tolerance
27%
Short Course Therapy
27%
Diastolic Dysfunction
27%
Extrapulmonary Tuberculosis
27%
Lung Tuberculosis
23%
Drug Resistant Tuberculosis
18%
Multidrug Resistant Tuberculosis
18%
Nutritional Status
18%
Ethambutol
13%
Body Mass Index
13%
Sleep Hygiene
10%
Nutrition
9%
Logistic Regression Analysis
9%
Streptomycin
9%
Isoniazid
9%
Extensively Drug Resistant Tuberculosis
9%
Human Immunodeficiency Virus
9%
Tuberculostatic Agent
9%
Pyrazinamide
9%
Rifampicin
9%
Infection
9%
Diabetes Mellitus
8%
Cardiac Catheterization
5%
Tissue Doppler Imaging
5%
Congestive Heart Failure
5%